{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:45:28Z","timestamp":1793814328447,"version":"4.6.1"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]},{"name":"2023 Arthritis Australia National Research Program","id":[{"id":"https:\/\/ror.org\/02wcz1374","id-type":"ROR","asserted-by":"crossref"}]},{"name":"The Hospital Research Foundation-Arthritis"},{"name":"2024 Royal Australasian College of Physicians Research Entry Scholarship","id":[{"id":"https:\/\/ror.org\/047hk9367","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Immune-mediated necrotizing myopathy (IMNM) with autoantibodies targeting 3-hydroxy-3-methylglutaryl-CoA reductase (anti-HMGCR) is considered a rare complication of statin therapy. We calculate the incidence of anti-HMGCR IMNM and describe clinical characteristics in four independent cohorts: Manchester (UK), Bristol (UK), Western Australia (WA, Australia) and South Australia (SA, Australia).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults (\u226518\u2009years) with anti-HMGCR IMNM (ENMC criteria; 2018\u20132023) were identified from myositis clinic and laboratory records. Nationwide UK anti-HMGCR testing was performed at Oxford University Hospital Laboratories and state-based WA\/SA testing at PathWest Laboratories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred and nine anti-HMGCR IMNM cases were identified (51% female, median 66\u2009years [IQR 58\u201372.2]) with median follow-up 2.3\u2009years [IQR 1.5\u20134.2]. Mean annual incidence was 2.9 cases\/million person-years. In statin users, incidence was 20.4 (UK) and 24.1 (WA\/SA) cases\/million statin-users\/year. One hundred and one patients were statin-exposed, mostly atorvastatin (77\/101, 76.2%). Median statin duration before diagnosis was 3\u2009years (range: 1\u2009month\u201323\u2009years). Eight (7.5%) were statin-na\u00efve and, compared with statin-exposed patients, younger (median 46.1 vs 67\u2009years, P\u2009=\u20090.02), frequently of non-white ethnicity (5\/8 vs 20\/77, P\u2009=\u20090.04) and more commonly had dysphagia (4\/8 vs 14\/94, P\u2009=\u20090.03). The median peak creatine kinase (CK) was 7020\u2009IU\/l (range: 964\u201339076), and 48\/105 (45.7%) received intravenous immunoglobulin. At follow-up, less than half had normal CK (50\/105 [47.6%]) or muscle power (48\/104 [46.2%]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>For the first time, we have calculated an incidence of anti-HMGCR IMNM using a large, multinational cohort. We highlight the refractory nature of anti-HMGCR IMNM. We also describe the unique phenotype of statin-na\u00efve anti-HMGCR IMNM, and the rare occurrence of self-limiting myopathy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf238","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T07:27:16Z","timestamp":1746689236000},"page":"4995-5003","source":"Crossref","is-referenced-by-count":20,"title":["The incidence of anti-HMGCR immune-mediated necrotizing myopathy: an Australian and UK retrospective multi-site cohort study"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1122-3384","authenticated-orcid":false,"given":"Thomas","family":"Khoo","sequence":"first","affiliation":[{"name":"Faculty of Health and Medical Sciences, School of Medicine, University of Adelaide , Adelaide, South Australia,","place":["Australia"]},{"name":"Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester , Manchester,","place":["UK"]},{"name":"Rheumatology Unit, Southern Adelaide Local Health Network , Adelaide, South Australia,","place":["Australia"]},{"name":"Rheumatology Unit, Royal Adelaide Hospital , Adelaide, South Australia,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Sir Charles Gairdner Hospital , Nedlands, Western Australia,","place":["Australia"]},{"name":"Department of Immunology, PathWest Laboratory Medicine , Perth, Western Australia,","place":["Australia"]},{"name":"Department of Clinical Immunology, Royal Perth Hospital , Nedlands, Western Australia,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya","family":"Limaye","sequence":"additional","affiliation":[{"name":"Faculty of Health and Medical Sciences, School of Medicine, University of Adelaide , Adelaide, South Australia,","place":["Australia"]},{"name":"Rheumatology Unit, Royal Adelaide Hospital , Adelaide, South Australia,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsha","family":"Gunawardena","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, North Bristol NHS Trust , Bristol,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Sadler","sequence":"additional","affiliation":[{"name":"Immunology Laboratory, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust , Oxford,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7248-0539","authenticated-orcid":false,"given":"Janine A","family":"Lamb","sequence":"additional","affiliation":[{"name":"Epidemiology and Public Health Group, School of Health Sciences, University of Manchester , Manchester,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Lyu","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester , Manchester,","place":["UK"]},{"name":"Epidemiology and Public Health Group, School of Health Sciences, University of Manchester , Manchester,","place":["UK"]},{"name":"Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine , Shanghai,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Brusch","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Sir Charles Gairdner Hospital , Nedlands, Western Australia,","place":["Australia"]},{"name":"Department of Immunology, PathWest Laboratory Medicine , Perth, Western Australia,","place":["Australia"]},{"name":"Neuromuscular Clinic, Perron Institute for Neurological and Translational Science, QEII Medical Centre , Nedlands, Western Australia,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrilee","family":"Needham","sequence":"additional","affiliation":[{"name":"Neuromuscular Clinic, Perron Institute for Neurological and Translational Science, QEII Medical Centre , Nedlands, Western Australia,","place":["Australia"]},{"name":"Department of Neurology, Fiona Stanley Hospital , Perth, Western Australia,","place":["Australia"]},{"name":"Institute for Immunology and Infectious Diseases, Murdoch University , Perth, Western Australia,","place":["Australia"]},{"name":"School of Medicine, University of Notre Dame , Perth, Western Australia,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keziah","family":"Austin","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, North Bristol NHS Trust , Bristol,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Bahadori","sequence":"additional","affiliation":[{"name":"Fiona Stanley Hospital , Perth, Western Australia,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8962-5642","authenticated-orcid":false,"given":"Maya H","family":"Buch","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester , Manchester,","place":["UK"]},{"name":"NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust , Manchester,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8215-6567","authenticated-orcid":false,"given":"Maciej","family":"Tomaszewski","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Sciences, Faculty of Medicine, Biology and Health, University of Manchester , Manchester,","place":["UK"]},{"name":"Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust Manchester, Manchester Royal Infirmary , Manchester,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B","family":"Lilleker","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester , Manchester,","place":["UK"]},{"name":"Manchester Centre for Clinical Neuroscience, Manchester Academic Health Science Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust , Salford,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6492-1288","authenticated-orcid":false,"given":"Hector","family":"Chinoy","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester , Manchester,","place":["UK"]},{"name":"NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust , Manchester,","place":["UK"]},{"name":"Department of Rheumatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre , Salford,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"key":"2025090315125332300_keaf238-B1","doi-asserted-by":"crossref","first-page":"e525","DOI":"10.3399\/bjgp20X710873","article-title":"Prescription of suboptimal statin treatment regimens: a retrospective cohort study of trends and variation in English primary care","volume":"70","author":"Curtis","year":"2020","journal-title":"Br J Gen Pract"},{"key":"2025090315125332300_keaf238-B2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2016.4700","article-title":"National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: insights from the Medical Expenditure Panel Survey","volume":"2","author":"Salami","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2025090315125332300_keaf238-B3","doi-asserted-by":"crossref","first-page":"100880","DOI":"10.1016\/j.cpcardiol.2021.100880","article-title":"Trends in the utilization of lipid-lowering medications in Australia: an analysis of national pharmacy claims data","volume":"47","author":"Talic","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"2025090315125332300_keaf238-B4","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"2025090315125332300_keaf238-B5","doi-asserted-by":"crossref","first-page":"e011765","DOI":"10.1161\/JAHA.118.011765","article-title":"Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM Registry","volume":"8","author":"Bradley","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2025090315125332300_keaf238-B6","doi-asserted-by":"crossref","first-page":"e004249","DOI":"10.1161\/CIRCOUTCOMES.117.004249","article-title":"Prevalence and management of symptoms associated with statin therapy in community practice: insights From the PALM (Patient and Provider Assessment of Lipid Management) Registry","volume":"11","author":"Navar","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2025090315125332300_keaf238-B7","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","article-title":"Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials","volume":"400","author":"Reith","year":"2022","journal-title":"Lancet"},{"key":"2025090315125332300_keaf238-B8","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/clpt.2014.121","article-title":"Phenotype standardization for statin-induced myotoxicity","volume":"96","author":"Alfirevic","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"2025090315125332300_keaf238-B9","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N Engl J Med"},{"key":"2025090315125332300_keaf238-B10","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-mediated necrotizing myopathy: clinical features and pathogenesis","volume":"16","author":"Allenbach","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2025090315125332300_keaf238-B11","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2025090315125332300_keaf238-B12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2025090315125332300_keaf238-B13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/acr.20662","article-title":"Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090315125332300_keaf238-B14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1471-2474-13-103","article-title":"Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis","volume":"13","author":"Smoyer-Tomic","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"key":"2025090315125332300_keaf238-B15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/03009742.2019.1672782","article-title":"Anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level","volume":"49","author":"Aggarwal","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"2025090315125332300_keaf238-B16","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1212\/NXI.0000000000000523","article-title":"Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy","volume":"6","author":"Mohassel","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025090315125332300_keaf238-B17","doi-asserted-by":"crossref","first-page":"103468","DOI":"10.1016\/j.autrev.2023.103468","article-title":"Anti-HMGCR immune-mediated necrotising myopathy: addressing the remaining issues","volume":"22","author":"Khoo","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2025090315125332300_keaf238-B18","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3899\/jrheum.160871","article-title":"Anti-HMGCR Autoantibodies in Juvenile Idiopathic Inflammatory Myopathies Identify a Rare but Clinically Important Subset of Patients","volume":"44","author":"Tansley","year":"2017","journal-title":"J Rheumatol"},{"key":"2025090315125332300_keaf238-B19","first-page":"787","article-title":"More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"56","author":"Tiniakou","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2025090315125332300_keaf238-B20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"2025090315125332300_keaf238-B21","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mus.24541","article-title":"Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy","volume":"52","author":"Limaye","year":"2015","journal-title":"Muscle Nerve"},{"key":"2025090315125332300_keaf238-B22","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1111\/imj.16004","article-title":"Clinical associations of patients with anti-3-hydroxy-3-methylglutaryl CoA reductase antibody-associated immune-mediated necrotising myopathy","volume":"53","author":"Tan","year":"2023","journal-title":"Intern Med J"},{"key":"2025090315125332300_keaf238-B23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cca.2017.07.011","article-title":"Detection of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme a reductase by ELISA in a reference laboratory setting","volume":"472","author":"Jaskowski","year":"2017","journal-title":"Clin Chim Acta"},{"key":"2025090315125332300_keaf238-B24","doi-asserted-by":"crossref","first-page":"405956","DOI":"10.1155\/2014\/405956","article-title":"Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies","volume":"2014","author":"Musset","year":"2014","journal-title":"J Immunol Res"},{"key":"2025090315125332300_keaf238-B25","volume-title":"Polymyositis, dermatomyositis, and inclusion body myositis","author":"Holton","year":"2013","edition":"2nd edn."},{"key":"2025090315125332300_keaf238-B26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1203475416665601","article-title":"Risk of Malignancy in Dermatomyositis and Polymyositis","volume":"21","author":"Qiang","year":"2017","journal-title":"J Cutan Med Surg"},{"key":"2025090315125332300_keaf238-B27","author":"National Disease Registration Service. England Cancer Prevalence Statistics [internet]","year":"2023"},{"key":"2025090315125332300_keaf238-B28"},{"key":"2025090315125332300_keaf238-B29","doi-asserted-by":"crossref","first-page":"298","DOI":"10.55563\/clinexprheumatol\/5y19bb","article-title":"Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies: incidence using different testing criteria, and case series","volume":"40","author":"Joseph","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2025090315125332300_keaf238-B30","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/rheumatology\/keae282","article-title":"Anti-HMGCR myopathy: estimated five-fold higher incidence in Polynesian compared to European populations in Aotearoa New Zealand","volume":"64","author":"Chow","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2025090315125332300_keaf238-B31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13075-019-2093-6","article-title":"Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients","volume":"22","author":"Meyer","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025090315125332300_keaf238-B32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.31128\/AJGP-06-20-5467","article-title":"Evolving worldwide approaches to lipid management and implications for Australian general practice","volume":"50","author":"Brett","year":"2021","journal-title":"Aust J Gen Pract"},{"key":"2025090315125332300_keaf238-B33","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain"},{"key":"2025090315125332300_keaf238-B34","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1212\/NXI.0000000000000290","article-title":"Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy","volume":"3","author":"Kadoya","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025090315125332300_keaf238-B35","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamaneurol.2015.1207","article-title":"Clinical features and treatment outcomes of necrotizing autoimmune myopathy","volume":"72","author":"Kassardjian","year":"2015","journal-title":"JAMA Neurol"},{"key":"2025090315125332300_keaf238-B36","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.autrev.2016.09.005","article-title":"Statin-associated autoimmune myopathy: a distinct new IFL pattern can increase the rate of HMGCR antibody detection by clinical laboratories","volume":"15","author":"Alvarado-Cardenas","year":"2016","journal-title":"Autoimmun Rev"},{"key":"2025090315125332300_keaf238-B37","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jacc.2016.04.037","article-title":"Statin-induced anti-HMGCR-associated myopathy","volume":"68","author":"Basharat","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2025090315125332300_keaf238-B38","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/rheumatology\/kev229","article-title":"Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience","volume":"54","author":"Klein","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2025090315125332300_keaf238-B39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.18773\/austprescr.2020.075","article-title":"Top 10 drugs 2019-20","volume":"43","author":"Do","year":"2020","journal-title":"Aust Prescr"},{"key":"2025090315125332300_keaf238-B40","author":"National Health Service (NHS) England Business Services Authority. Prescription Cost Analysis England 2020\/21 [internet]"},{"key":"2025090315125332300_keaf238-B41","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"2025090315125332300_keaf238-B42","doi-asserted-by":"crossref","first-page":"e0141616","DOI":"10.1371\/journal.pone.0141616","article-title":"Clinical Characteristics of Anti-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Antibodies in Chinese Patients with Idiopathic Inflammatory Myopathies","volume":"10","author":"Ge","year":"2015","journal-title":"PLoS One"},{"key":"2025090315125332300_keaf238-B43","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00296-021-05063-3","article-title":"The prevalence and clinical characteristics of anti-HMGCR (anti-3-hydroxy-3-methyl-glutaryl-coenzyme A reductase) antibodies in idiopathic inflammatory myopathy: an analysis from the MyoCite registry","volume":"42","author":"Gupta","year":"2022","journal-title":"Rheumatol Int"},{"key":"2025090315125332300_keaf238-B44","first-page":"291","article-title":"Immune-mediated necrotizing myopathy in a multi-ethnic Malaysian cohort","volume":"26","author":"Tan","year":"2021","journal-title":"Neurology Asia"},{"key":"2025090315125332300_keaf238-B45","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jnnp-2016-313166","article-title":"Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy","volume":"87","author":"Watanabe","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025090315125332300_keaf238-B46","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.2337\/dc18-1453","article-title":"Biochemical urine testing of adherence to cardiovascular medications reveals high rates of nonadherence in people attending their annual review for type 2 diabetes","volume":"42","author":"Patel","year":"2019","journal-title":"Diabetes Care"},{"key":"2025090315125332300_keaf238-B47","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.nmd.2020.02.003","article-title":"Clinical and histological features of immune-mediated necrotising myopathy: a multi-centre South Australian cohort study","volume":"30","author":"Day","year":"2020","journal-title":"Neuromuscul Disord"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf238\/63141313\/keaf238.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/9\/4995\/63141313\/keaf238.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/9\/4995\/63141313\/keaf238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:13:01Z","timestamp":1756926781000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/9\/4995\/8128346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5,10]]},"published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf238","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,5,10]]}}}